Trials / Available
AvailableNCT06751524
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Botensilimab and Balstilimab Expanded Access Program
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Agenus Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Detailed description
This EAP is available for indications where there is reasonable scientific basis for use. Availability will depend on territory eligibility.
Conditions
- Colorectal Cancer (CRC)
- Pancreatic Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Hepatocellular Carcinoma (HCC)
- Melanoma
- Sarcoma
- Ovarian Cancer
- Prostate Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botensilimab | Administered via an intravenous (IV) infusion of Botensilimab + Balstilimab combination (BOT+BAL). |
| DRUG | Balstililmab | Administered via an IV infusion of Botensilimab + Balstilimab combination (BOT+BAL). |
Timeline
- First posted
- 2024-12-30
- Last updated
- 2024-12-30
Source: ClinicalTrials.gov record NCT06751524. Inclusion in this directory is not an endorsement.